Celanese Corporation (CE) Balance Sheet

The decline in total assets and equity over the past ten quarters reflects a combination of asset write-downs, including a $1.3B reduction in goodwill from 2024Q3 to 2025Q2, and ongoing net losses. The equity base has shrunk by over 40% from its 2024Q1 level, which appears to be driven by cumulative losses and impairments rather than shareholder distributions. This trajectory suggests that the company's balance sheet is weakening, with the erosion of equity cushion potentially limiting financial flexibility.

While the company has reduced absolute debt by approximately $1.5B over the period, the equity base has contracted even faster, causing leverage metrics to deteriorate. The D/E ratio of 2.69 in 2026Q2 is significantly higher than the peer average of around 1.0, indicating a highly leveraged capital structure. This elevated leverage appears to be a consequence of the M&M acquisition and subsequent impairments, and it may constrain the company's ability to refinance or absorb further shocks.

The significant reduction in goodwill suggests that the company has recognized impairment charges, likely related to the M&M acquisition, which may indicate that expected synergies are not materializing as initially projected. The modest decline in PPE, from $5.9B to $5.2B, reflects depreciation and reduced capital expenditure, which fell from $137M in 2024Q1 to $62M in 2026Q2. This defensive capex stance may preserve cash in the near term but could impair long-term competitiveness if sustained.

The decline in retained earnings is consistent with the net losses reported in several quarters, including a -80.8% net margin in 2024Q4 and -12.2% in the latest quarter. The equity base has been further eroded by impairments, which are non-cash but reduce book value. With equity at only $4.2B against total debt of $12.3B, the company's solvency buffer appears thin, and any additional losses could push equity toward negative territory.

The current ratio has remained above 1.0, but it has declined from a peak of 2.05 in 2025Q2, suggesting that current assets are not growing as fast as current liabilities. Cash levels have improved from the 2024Q4 trough, but the absolute amount is modest relative to the company's debt load and operating scale. Given the cyclicality of the chemical industry and the ongoing integration costs, this liquidity buffer may be adequate for near-term obligations but could be strained if operating cash flows deteriorate further.